{"id":"apl-1202-treatment","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"APL-1202 is an immunotherapy that works by blocking the PD-1/PD-L1 interaction, which is a key checkpoint in the immune system. This allows the immune system to recognize and attack cancer cells more effectively.","oneSentence":"APL-1202 treatment targets the PD-1/PD-L1 pathway to modulate the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:48.381Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT06435039","phase":"PHASE1","title":"A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers","status":"TERMINATED","sponsor":"Syneos Health","startDate":"2024-06-21","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT06034015","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers","status":"UNKNOWN","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","startDate":"2023-09-09","conditions":"Bladder Cancer","enrollment":48},{"nctId":"NCT04490993","phase":"PHASE3","title":"Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients","status":"UNKNOWN","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","startDate":"2017-03-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":359},{"nctId":"NCT04813107","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","startDate":"2021-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":79},{"nctId":"NCT04736394","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients","status":"UNKNOWN","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","startDate":"2021-09-29","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":800},{"nctId":"NCT04601766","phase":"PHASE1","title":"A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets","status":"COMPLETED","sponsor":"Asieris Pharmaceuticals (AUS) Pty Ltd.","startDate":"2020-10-30","conditions":"Bladder Cancer","enrollment":12},{"nctId":"NCT04498702","phase":"PHASE2","title":"Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy","status":"COMPLETED","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","startDate":"2014-05-13","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":41},{"nctId":"NCT03672240","phase":"PHASE1, PHASE2","title":"Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment","status":"COMPLETED","sponsor":"Asieris Pharmaceutical Technologies Co., Ltd.","startDate":"2018-11-30","conditions":"Non-Muscle Invasive Bladder Cancer (NMIBC)","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"APL-1202 treatment","genericName":"APL-1202 treatment","companyName":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","companyId":"jiangsu-yahong-meditech-co-ltd-aka-asieris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APL-1202 treatment targets the PD-1/PD-L1 pathway to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}